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Abstract
Introduction: The aim of the study was to compare the efficacy of half-dose,
long-acting GnRH analogue (Diphereline) with Suprefact in IVF/ICSI (in vitro
fertilization/intracytoplasmic sperm injection) cycles.
Material and methods: In this randomized clinical trial performed in Royan
Institute, 126 infertile women who were first time candidates for IVF/ICSI were
enrolled. Patients were randomly divided into two groups by using a random
number table. In one group, 62 patients received a single half dose, 1.87 mg
Diphereline, in mid-luteal phase. In the other group, 64 cases were treated with
buserelin from the previous mid-luteal phase. P value less than 0.05 was
considered significant.
Results: The mean age of patients in the Diphereline and Suprefact groups was
27.9 ±3.6 and 29.6 ±3.5 years, respectively (p = 0.01). In the Diphereline group,
the mean number of used gonadotropins was 25.6 ±12.1 ampoules, while in the
second group it was 25.9 ±8.5 ampoules. Numbers of retrieved and MII oocytes
were significantly higher in the Diphereline group (12.1 ±6.3 and 9.6 ±5.5) in
comparison to the Suprefact group (9.4 ±6.4 and 7.2 ±5.1). Although the number
of developed embryos in the Diphereline group was statistically higher than in
the Suprefact group (6.1 ±3.9 vs. 4.7 ±3.4, p = 0.04) there was no significant
difference in pregnancy rate (37.1%, 95% CI [26.16-49.54] vs. 37.5%, 95% CI [26.67-
49.75]). 
Conclusions: A half-dose, long-acting GnRH agonist can be successfully used in
ovarian stimulation and produces a higher number of MII oocytes and embryos.
The pregnancy rates with this method are acceptable. 
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Introduction
Ovulation induction is the most critical and important step in ART cycles.
In the past, human gonadotropins have been widely used alone; however,
during the past few decades, due to a high prevalence of premature LH
surge and its negative effects on oocytes [1], gonadotropin-releasing
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hormone (GnRH) analogues (GnRHa) have been
widely used for pituitary desensitization during
controlled ovarian stimulation (COS). The long
protocol with GnRHa has been generally accepted
for pituitary suppression because of decreases in
cancellation rates, prevention of premature
luteinization and endogenous luteinizing hormone
(LH) surges, an increase in multiple follicular growth
[2] and potentially better treatment cycle timing [3].
Nowadays, many types of short- and long-acting
GnRH analogues are being used [4]. The use of
a single-dose depot long-acting GnRH agonist in
COS cycles, instead of a daily low-dose preparation,
would be more convenient for patients because it
eliminates multiple injections and facilitates
stimulation [5]. It is welcomed, both by patients and
physicians, because of the convenience of a single
administration [6]. However, when profound
pituitary desensitization is induced, there is an
increase in the number of used gonadotropin
ampoules and the duration of the COS cycle
without improving pregnancy rates or other clinical
outcomes [7]. Although some researchers such as
Genon et al. showed superiority of a short-acting
GnRH-agonist (buserelin) over the long-acting
agents (Decapeptyl) in achievement of pregnancy
and its outcome [8], others did not find any
significant differences in clinical pregnancy rate,
implantation rate, and early pregnancy loss rate
between the two groups and suggested that
a single administration of long-acting GnRHa is
a useful alternative for improving patient
convenience, with clinical outcomes comparable to
daily administrations of short-acting GnRHa in COH
(controlled ovarian hyperstimulation), for IVF-ET
cycles [9]. In addition to the controversy in type of
GnRH agonist used (long-acting vs. short-acting),
another challenging issue is the dose of long-acting
GnRH agonist. 
Some studies have compared the outcome of
halving the dose of GnRH agonist depot with its
full-dose administration [6, 10, 11]. For example, Tsai
et al. [12] and Hsieh et al. [13] showed that the half-
dose depot leuprolide acetate resulted in
comparable clinical outcomes with the standard
daily injections in the long GnRHa protocol.
In spite of some studies in this regard, use of
a long-acting instead of short-acting form of GnRH
agonist and its dose (full dose or half dose) remain
controversial topics in ART.
The aim of this study was to use a single half-
dose depot GnRH agonist (Diphereline) instead of
the routine daily subcutaneous short-acting form
(Suprefact) in the long protocol ICSI/IVF cycles in
a randomized clinical trial and compare the
stimulation time, number of retrieved oocytes and
embryos and pregnancy rate between the two
groups.
Material and methods
In this randomized clinical trial, 126 patients who
were first time candidates for ICSI/IVF at Royan
Institute were enrolled between April 2005 and March
2006. All patients signed an informed consent form.
This study was approved by the Royan Institute Ethics
Committee. 
The patients were randomly divided into two
groups by using a random number table. Because of
the different drug administration routes, we could not
blind this study. All patients were 20-35 years old. We
excluded patients aged more than 35 years old or
with follicle-stimulating hormone (FSH) > 8 mIU/ml
because we wanted to survey the efficacy of these
two drugs in normoresponsive patients. Except for
moderate to severe endometriosis, other causes of
infertility were included in this study. In all patients,
the serum FSH level was less than 8 mIU/ml on day
3 of the previous menstrual cycle. Patients with
ovarian or pelvic surgery were also excluded. 
After randomization, 62 patients in group I (half-
dose Diphereline) and 64 patients in group II (daily
injection of Suprefact) were studied. All patients
underwent transvaginal sonography on the 3rd day
of the menstruation cycle; and serum LH, FSH and
oestradiol were checked on the same day. Low-dose
oral contraceptive pills (ethinyl oestradiol 30 μg 
+ levonorgestrel 150 μg) were administered from 
day 5 of the menstrual period until day 21. On day 21
of the cycle, in group I, a half dose (1.85 mg) of long-
acting GnRH agonist (Diphereline S.R., 3.75 mg, IPSEN,
France) was intramuscularly injected in a single dose,
whereas in group II, a subcutaneous GnRH agonist
(Suprefact, Hoechst, Germany), at a standard dose of
0.5 mg, was started on day 21 and repeated until the
new menstruation period. At this time daily doses of
Suprefact were reduced to 0.25 mg until human
chorionic gonadotropin (hCG) injection. For both
groups, from day 3 of the new menstrual cycle, 
2 ampoules per day of human menopausal
gonadotropin (hMG; Monogon 75 U FSH/75 U LH,
Ferring, Germany) were intra  muscularly injected and
at day 6 of gonadotropin stimulation, the first control
transvaginal sonography was done. If the follicular
response was not adequate, hMG ampoules were
increased and serial sonography was performed every
other day and repeated until at least 2-3 follicles with
18-20 mm diameter were seen. At that time patients
received 10,000 IU hCG (Profasi, 10000 IU, 
Serono, the Netherlands) injected intramuscularly, 
and transvaginal oocyte retrieval was performed 34-
36 hours later. After doing an IVF or ICSI procedure in
the laboratory, the embryos were transferred 2-3 days
later. The quality of embryos was assessed according
to the number of blastomeres and cytoplasmic
fragmentation. High quality embryos were defined by
0% fragmentation and all blastomeres with similar
size [14].Arch Med Sci 6, December / 2010 947
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In both groups on day 8, if less than 3 follicles with
diameters more than 14 mm were seen, the cycle was
cancelled. The number of hMG ampoules and days for
ovarian simulation, rate of occurrence of ovarian
hyperstimulation syndrome (OHSS), cycle cancellation,
number and quality of retrieved oocytes, number of
metaphase II oocytes (MII), number and quality of
embryos, pregnancy and miscarriage rates were
compared between the two groups. 
For luteal phase support, all patients received
400 mg vaginal supposition of progesterone (Cyclogest
400 mg, Alpharma, England) twice per day starting on
the day of oocyte retrieval. Serum β hCG levels more
than 50 IU/l were considered as chemical pregnancy.
Four to five weeks after embryo transfer, pregnancy
results were assessed with TVS.
The Statistical Package for the Social Sciences version
15 software was used to analyse the data. A level of
0.05 was considered significant. Independent samples
t-test was used for continuous response measures in
both groups’ variables. Prevalence differences were
analysed by t-test, χ2 test and Fisher’s exact test.
Results
In this clinical trial, after randomization, 62
patients in group I (half-dose Diphereline) and
64 patients in group II (daily injection of
Suprefact) were studied. About 90% of studied
patients underwent ICSI (90.3% in group I and
90.6% in group II). Mean body mass index (BMI)
and duration of infertility in the two groups were
not significantly different (Table I). Also, the
causes of infertility between the two groups
were matched (Table I). The difference in mean
age between the two groups was statistically
significant (p = 0.01). There were significant
differences in the numbers of retrieved oocytes,
metaphase II oocytes and numbers of embryos
between the two groups. The mean number of
used gonadotropin ampoules, duration of
ovarian stimulation, and numbers of good
quality embryos and transferred embryos were
not significantly different between the groups
(Table II).
Group I (Diphereline)G roup II (Suprefact) p value
N = 62 N = 64
Mean age [years] 27.9 ±3.6a 29.6 ±3.5a 0.01*
Mean BMI [kg/m2] 24.7 ±2.5a 25.57 ±3.1a NS
Duration of infertility [years] 7.4 ±4.01a 8.6 ±3.62a NS
Causes of infertility, n (%) NS
Male factor 32 (51.61)b 35 (54.68)b
Female factor 20 (32.29)b 18 (28.12)b
PCOs 7 (11.3)b 5 (7.8)b
Endometriosis 4 (6.4)b 7 (10.9)b
Tubal factor 9 (14.5)b 6 (9.5)b
Unexplained 10 (16.1)b 11 (17.2)b
Table I. Basic characteristics of studied patients 
apresented as mean ± SD
bpresented as number (percentage)
*Significant difference (p < 0.05)
NS – not significant 
Group I (Diphereline)G roup II (Suprefact) p value
N = 62 N = 64
Ampoules of HMG 25.6 ±12.1a 25.9 ±8.5a NS
Days of stimulation  10.32 ±2.03a 9.95 ±0.91a NS
Retrieved oocytes 12.11 ±6.32a 9.43 ±6.4a 0.02*
Oocytes in stage MII 9.6 ±5.54a 7.23 ±5.12a 0.015*
Numbers of embryos 6.1 ±3.9a 4.73 ±3.45a 0.04*
Numbers of transferred embryos 2.31 ±0.733a 2.29 ±0.726a NS
Numbers of morphologically good embryos 4.9 ±3.2a 3.9 ±3.1a NS
Clinical pregnancy rate [%] 37.1 37.5  NS
Miscarriage rate [%] 8.7 8.33  NS
Number of ICSI cycles, n (%) 56 (90.3) 58 (90.6) NS
Table II. Early results and clinical outcomes of ART cycles in two groups
apresented as mean ± SD
NS – not significant 
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Pregnancy rate in the Diphereline group was
37.1% (95% CI [26.16-49.54]) (23 from 62 patients)
and 37.5% (95% CI [26.67-49.75]) (24 from 64
patients) in the Suprefact group but this difference
was not statistically significant (p = 0.92). In group
I, 17 pregnancies were single, 4 pregnancies were
twins, and 2 miscarriages occurred. In group II, 20
pregnancies were single, 2 pregnancies were twins,
and 2 miscarriages occurred. These differences
between the two groups were not statistically
significant. Severe OHSS did not occur in either
groups. There was no cancellation of treatment in
either group.
Discussion
Assisted reproduction treatments are very
stressful and tiring for infertile couples. Any
simplification in the pharmacological treatment is
therefore a welcome development [6]. Depot GnRHa
in long protocols offers the advantages of better
compliance, convenience, and economy for patients,
with less stress over injections and risk of infection.
However, depot formulations require more
gonadotropin ampoules, which are needed for
ovarian stimulation, and a significantly longer
duration of ovarian stimulation than daily GnRHa [7].
Another issue related to depot GnRH agonist is
choosing the best dose (half vs. full dose). Yim et al.
compared half-dose depot GnRH analogues with full-
dose preparations in IVF cycles. They suggested that
the use of a lower dose appears to be equally
effective and could contribute to a reduction in the
cost of treatment [11].
Dal Prato et al. showed that a half dose of depot
triptorelin can be successfully used in ovarian
stimulation for IVF. In their study, the effect of the
different doses of triptorelin (half dose vs. full dose)
on the pituitary was quite different. They confirmed
that reduced pituitary desensitization is induced by
half-dose triptorelin. Furthermore, 1.87 mg triptorelin
administration proved sufficient to prevent an LH
surge [6].
Albuquerque et al. in a meta-analysis study [7]
showed that there is insufficient evidence that the
depot GnRH agonist formulation is better or worse
than using a daily GnRH agonist in the long protocol
for pituitary desensitization in IVF cycles; so clinicians
should use whichever is more convenient [7].
According to their recommendations, the present
study was done on infertile women with both ovaries
undergoing their first IVF cycles. In the present study,
the efficacy of half-dose, long-acting GnRH agonist
(Diphereline) was compared with daily injections of
a short-acting GnRH agonist (Suprefact). Although the
difference in mean age between the two groups was
significant, the mean age of both groups was below
35 years. According to recent work by Gomes, age
more than 35 years old, especially 40, had a critical
effect on IVF outcome. Gomes et al. divided IVF
patients into 3 groups according to their age (age
equal to or less than 35, age 36-39, and age equal to
or more than 40). They found that the number of
oocytes obtained in the G ≥40 group was significantly
lower than in the other two groups, but the percentage
of good quality embryos was not statistically different
and the fertilization rate was similar in the three
groups. The average number of transferred embryos
and pregnancy rates were statistically lower in the G
≥ 40 group in comparison with those observed for
the G ≤ 35 and 36-39 groups [15]. 
In the present study, pregnancy rates were
comparable in the two groups (37.1% in the
Diphereline group vs. 37.5% in the Suprefact group).
These findings were in overall agreement with similar
studies evaluating half-dose depot GnRH agonist with
daily administration of short-acting forms [4, 16].
Taheripanah et al. evaluated the efficacy of low-
dose, long-acting GnRHa (Decapeptyl) for pituitary
desensitization and compared the outcome of ART
cycles to a long protocol of short-acting GnRHa
(buserelin). In their report, there was no significant
difference in cancellation, pregnancy rate and
gonadotropin dose between the two groups [4].
Although the mean numbers of retrieved oocytes,
metaphase II oocytes and embryos in the present
study were statistically higher in the Diphereline
group than in the Suprefact group, because of their
significantly lower mean age, we could not draw any
conclusion. It could be suggested that the half dose
of long-acting GnRH agonist in comparison to short-
acting components did not cause profound pituitary
suppression and lead to an adverse effect on ovaries.
In addition, use of Diphereline (half dose) is more
convenient because of the need for only one injection
in comparison with Suprefact, which needs daily
injections. The need for a single injection increases
patients’ compliance for treatment.
In conclusion, this study showed that half-dose,
long-acting GnRH agonist could have a comparable
outcome to short-acting components. Also there
were no significant adverse effects (including severe
OHSS) of long-acting GnRH agonist in comparison
to the short-acting analogue. However, further
multicentre clinical trials with matched cases and
larger sample sizes are recommended.
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